Immunome is a clinical-stage oncology company focused on developing innovative targeted therapies aimed at improving cancer patient outcomes. The company is advancing a diverse portfolio of therapeutics, leveraging the expertise of its leadership team, which has significant experience in the design and commercialization of advanced cancer treatments. Among its offerings are antibody-drug conjugate therapies (ADCs), which combine antibodies with cytotoxic drugs to selectively target and kill cancer cells. Immunome's pipeline features several promising candidates, including AL102, a gamma secretase inhibitor currently in a Phase 3 trial for desmoid tumors, and two additional therapies, IM-1021 and IM-3050, which are a ROR1 ADC and a FAP-targeted radioligand, respectively.

The company is committed to advancing both first-in-class and best-in-class therapies, with a focus on targeted oncology solutions. Immunome's strategic approach includes the development of discovery-stage ADCs and the preparation for Investigational New Drug (IND) submissions for IM-1021 and IM-3050, anticipated in early 2025. This commitment to innovation and targeted treatment positions Immunome as a key player in the oncology landscape, aiming to deliver transformative therapies that can significantly enhance treatment outcomes for cancer patients.

United States

Immunome Inc., a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens. The company was founded in 2006 and is based in Exton, Pennsylvania.

Cancer

Immune System Diseases

Immunome

COVID-19

IMM-BCP-01 is a three-antibody cocktail targeting non-overlapping regions of the Spike protein of SARS-CoV-2, including highly conserved, subdominant epitopes, which elicits both ACE2 and non-ACE2 dependent neutralization, and induces natural viral clearance mechanisms, such as antibody dependent cellular cytotoxicity, complement activation and phagocytosis. When tested in vivo, these mechanisms combine to significantly reduce viral load in lungs of the hamsters infected with SARS-CoV-2. IMM-BCP-01 neutralizes all variants of SARS-CoV-2 tested to date in vitro.

Immunome

Company Details